Philma Opinaldo
Internal Medicine · Poplar Bluff, MONPI 1023128840
Payments from drug & device makers
Across 105 payments — averaging $14.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$264
- Supernus Pharmaceuticals, Inc.$198
- Novo Nordisk$173
- Astellas Pharma US Inc$141
- AbbVie$112
- GSK$109
- plus $540 from 19 others
What the payments were for
- Food & beverage$1,37389%
- Education$16311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $264 |
| Supernus Pharmaceuticals, Inc. | 12 | $198 |
| Novo Nordisk | 12 | $173 |
| Astellas Pharma US Inc | 4 | $141 |
| AbbVie(2 entities) | 6 | $112 |
| GSK | 15 | $109 |
| Boehringer Ingelheim | 6 | $95 |
| Lilly USA, LLC | 5 | $80 |
| Amgen | 3 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Amarin Pharma, Inc. | 3 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Eisai Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $28 |
| Pfizer | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Circassia Inc. | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| Grifols USA, LLC | 1 | $12 |
| Cardiovascular Systems Inc. | 1 | $2 |
How this compares
$1,536 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 337 | $249,327 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 278 | $203,187 |
| OzempicSemaglutide | 173 | $177,794 |
| TrulicityDulaglutide | 150 | $153,155 |
| LinzessLinaclotide | 193 | $119,647 |
| FarxigaDapagliflozin Propanediol | 152 | $111,297 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 112 | $85,625 |
| Tresiba Flextouch U-200Insulin Degludec | 87 | $80,617 |
| EliquisApixaban | 115 | $74,833 |
| RexultiBrexpiprazole | 44 | $64,264 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 96 | $48,994 |
| MyrbetriqMirabegron | 78 | $46,961 |
| XareltoRivaroxaban | 53 | $46,260 |
| JanuviaSitagliptin Phosphate | 48 | $38,740 |
| RybelsusSemaglutide | 34 | $36,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $95 | $301,647418 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix, Breo Ellipta, Arexvy | $109 | $295,527526 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $264 | $215,758340 claims |
| Novo NordiskOzempic, Rybelsus | $173 | $213,934207 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $80 | $172,663169 claims |
| AbbVieLinzess, Vraylar | $112 | $145,253211 claims |
| PfizerEliquis | $24 | $74,833115 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $15 | $64,26444 claims |
| MerckJanuvia, Janumet | $13 | $56,71578 claims |
| Astellas Pharma US IncMyrbetriq | $141 | $46,96178 claims |
| Johnson & JohnsonXarelto | $28 | $46,26053 claims |
| AmgenProlia | $49 | $29,05217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Poplar Bluff
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.